News

Combo Therapy Regimen a Potential New Standard for Recurrent Ovarian Cancer

05/21/2020

Carboplatin plus pegylated liposomal doxorubicin and bevacizumab has been posited as a new standard treatment for recurrent ovarian cancer, according to a phase 3 trial.

Carboplatin plus pegylated...

05/21/2020

Oncology

News

Anetumab Ravtansine Shows Encouraging Activity in Multiple Solid Tumor Types

05/12/2020

Anetumab ravtansine yielded manageable safety and encouraging antitumor activity in a study of heavily pretreated patients with mesothelin-expressing solid tumors.

Anetumab ravtansine yielded...

05/12/2020

Oncology

News

FDA Approves Olaparib–Bevacizumab Combo as Maintenance for Ovarian Cancer

05/08/2020

The FDA has approved olaparib plus bevacizumab as maintenance therapy for adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancers.

The FDA has approved olaparib...

05/08/2020

Oncology

News

FDA Approves Niraparib as Maintenance Therapy for Advanced Ovarian Cancer

04/29/2020

The FDA has approved niraparib for use as maintenance therapy in certain adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The FDA has approved niraparib...

04/29/2020

Oncology

News

Nivolumab–Ipilimumab Yields Greater Response in Ovarian Cancer Than Nivolumab Alone

04/14/2020

Combining nivolumab with ipilimumab led to a greater response rate and longer PFS than nivolumab alone in patients with epithelial ovarian cancer.

Combining nivolumab with...

04/14/2020

Oncology

News

Durvalumab–PLD Combo Promising for Platinum-Resistant Recurrent Ovarian Cancer

04/13/2020

Durvalumab plus PLD has shown promising efficacy in patients with platinum-resistant recurrent ovarian cancer.

Durvalumab plus PLD has shown...

04/13/2020

Oncology

News

Gemcitabine–Pazopanib Combo Shows Antitumor Efficacy in Ovarian Cancer

04/13/2020

Findings from a phase 2 study showed that adding pazopanib to gemcitabine enhanced antitumor activity in patients with ovarian cancer.

Findings from a phase 2 study...

04/13/2020

Oncology

News

Olaparib Yields Better Response, Survival Than Chemo in Relapsed Ovarian Cancer

03/12/2020

In pretreated patients with platinum-sensitive relapsed ovarian cancer, olaparib significantly improved ORR and PFS versus nonplatinum chemo.

In pretreated patients with...

03/12/2020

Oncology

News

OS Preferred End Point for Trials of First-Line/Maintenance Therapy in Ovarian Cancer

01/21/2020

A systematic review and analysis of several independent studies suggests that OS is the preferred end point in trials examining first-line or maintenance therapy for ovarian cancer.

A systematic review and analysis...

01/21/2020

Oncology

News

Type O Cervicovaginal Microbiota Linked to Higher Risk for Ovarian Cancer

01/06/2020

Findings from a recent study show that ovarian cancer is significantly associated with having a community type O cervicovaginal microbiota.

Findings from a recent study...

01/06/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology